Based on these observations, it appears that, rather than imposing a brief time constraint for all patients undergoing TURBT, prioritizing timely definitive treatment may be particularly crucial for patients with advanced tumours beyond TaG1‐2, which necessitates a meticulous selection of this cohort for more intricate management.6, 17. Here, CNTN2 is linked to neoplasm.